|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 405/14 | |
| C07D 401/12 | |||
| A61K 31/517 | |||
| A61P 35/00 | |||
| A61P 25/28 |
| (11) | Patento numeris | 3438107 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17869669.6 |
| Europos patento paraiškos padavimo data | 2017-10-17 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-02-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-06-10 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2017/106616 |
| Data | 2017-10-17 |
| (87) | Numeris | WO 2018/086446 |
| Data | 2018-05-17 |
| (30) | Numeris | Data | Šalis |
| 201610982608 | 2016-11-08 | CN |
| (72) |
ZHONG, Wei, CN
|
| (73) |
Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd.,
Room E8, 3rd Floor, Building 6 No.4299 Jindu Road Minhang District, Shanghai 201108,
CN
|
| (54) | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY |
| SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY |